1. RODNA
  2. CONICET
  3. CONICET
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.creatorMacdougall, Iain C.-
dc.creatorBircher, Andreas J.-
dc.creatorEckardt, Kai Uwe-
dc.creatorObrador, Gregorio T.-
dc.creatorPollock, Carol A.-
dc.creatorStenvinkel, Peter-
dc.creatorSwinkels, Dorine W.-
dc.creatorWanner, Christoph-
dc.creatorWeiss, Günter-
dc.creatorChertow, Glenn M.-
dc.creatorToblli, Jorge Eduardo-
dc.date2017-06-05T18:38:22Z-
dc.date2017-06-05T18:38:22Z-
dc.date2016-01-
dc.date2017-06-05T14:48:05Z-
dc.date.accessioned2019-04-29T15:53:44Z-
dc.date.available2019-04-29T15:53:44Z-
dc.date.issued2016-01-
dc.identifierMacdougall, Iain C.; Bircher, Andreas J.; Eckardt, Kai Uwe; Obrador, Gregorio T.; Pollock, Carol A.; et al.; Iron management in chronic kidney disease: Conclusions from a "kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference; Nature Publishing Group; Kidney International; 89; 1; 1-2016; 28-39-
dc.identifier0085-2538-
dc.identifierhttp://hdl.handle.net/11336/17500-
dc.identifier.urihttp://rodna.bn.gov.ar:8080/jspui/handle/bnmm/304882-
dc.descriptionBefore the introduction of erythropoiesis-stimulating agents (ESAs) in 1989, repeated transfusions given to patients with end-stage renal disease caused iron overload, and the need for supplemental iron was rare. However, with the widespread introduction of ESAs, it was recognized that supplemental iron was necessary to optimize hemoglobin response and allow reduction of the ESA dose for economic reasons and recent concerns about ESA safety. Iron supplementation was also found to be more efficacious via intravenous compared to oral administration, and the use of intravenous iron has escalated in recent years. The safety of various iron compounds has been of theoretical concern due to their potential to induce iron overload, oxidative stress, hypersensitivity reactions, and a permissive environment for infectious processes. Therefore, an expert group was convened to assess the benefits and risks of parenteral iron, and to provide strategies for its optimal use while mitigating the risk for acute reactions and other adverse effects.-
dc.descriptionFil: Macdougall, Iain C.. King's College Hospital Nhs Foundation Trust; Reino Unido-
dc.descriptionFil: Bircher, Andreas J.. Universitatsspital Basel; Suiza-
dc.descriptionFil: Eckardt, Kai Uwe. Universitat Erlangen-nuremberg; Alemania-
dc.descriptionFil: Obrador, Gregorio T.. Universidad Panamericana; México-
dc.descriptionFil: Pollock, Carol A.. The University Of Sydney; Australia. Royal North Shore Hospital; Australia-
dc.descriptionFil: Stenvinkel, Peter. Karolinska University Hospital; Suecia-
dc.descriptionFil: Swinkels, Dorine W.. Radboud University Nijmegen Medical Centre; Países Bajos-
dc.descriptionFil: Wanner, Christoph. Universitatsklinikum Wurzburg; Alemania-
dc.descriptionFil: Weiss, Günter. Medizinische Universitat Innsbruck; Austria-
dc.descriptionFil: Chertow, Glenn M.. University Of Stanford; Estados Unidos-
dc.descriptionFil: Toblli, Jorge Eduardo. Hospital Alemán. Laboratorio de Medicina Experimental; Argentina. Universidad de Buenos Aires. Facultad de Medicina; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina-
dc.formatapplication/pdf-
dc.formatapplication/pdf-
dc.languageeng-
dc.publisherNature Publishing Group-
dc.relationinfo:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1016/j.kint.2015.10.002-
dc.relationinfo:eu-repo/semantics/altIdentifier/url/http://www.sciencedirect.com/science/article/pii/S0085253815000034-
dc.rightsinfo:eu-repo/semantics/restrictedAccess-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.5/ar/-
dc.sourcereponame:CONICET Digital (CONICET)-
dc.sourceinstname:Consejo Nacional de Investigaciones Científicas y Técnicas-
dc.sourceinstacron:CONICET-
dc.subjectCHRONIC KIDNEY DISEASE-
dc.subjectHYPERSENSITIVITY-
dc.subjectINFECTIONS-
dc.subjectIRON-
dc.subjectOVERLOAD-
dc.subjectOXIDATIVE STRESS-
dc.subjectHematología-
dc.subjectMedicina Clínica-
dc.subjectCIENCIAS MÉDICAS Y DE LA SALUD-
dc.titleIron management in chronic kidney disease: Conclusions from a "kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.typeinfo:ar-repo/semantics/articulo-
Aparece en las colecciones: CONICET

Ficheros en este ítem:
No hay ficheros asociados a este ítem.
Mostrar el registro sencillo del ítem